Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Below Two Hundred Day Moving Average – Here’s Why

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $28.05 and traded as low as $20.17. Capricor Therapeutics shares last traded at $20.61, with a volume of 1,273,818 shares trading hands.

Analyst Ratings Changes

Several analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Capricor Therapeutics in a research note on Wednesday, May 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Monday, June 15th. LADENBURG THALM/SH SH upgraded Capricor Therapeutics to a “strong-buy” rating in a report on Thursday, June 25th. Finally, Roth Capital reaffirmed a “buy” rating and set a $38.00 price target on shares of Capricor Therapeutics in a research report on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $53.67.

Capricor Therapeutics Stock Down 4.2%

The company has a market capitalization of $1.19 billion, a P/E ratio of -8.88 and a beta of 0.42. The business has a fifty day moving average price of $27.42 and a 200 day moving average price of $28.05.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). As a group, equities analysts forecast that Capricor Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Insider Activity at Capricor Therapeutics

In related news, CFO Anthony Bergmann sold 24,100 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $30.38, for a total value of $732,158.00. Following the completion of the transaction, the chief financial officer owned 11,223 shares of the company’s stock, valued at approximately $340,954.74. This trade represents a 68.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 50,000 shares of company stock valued at $1,551,658 over the last 90 days. Insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On Capricor Therapeutics

A number of large investors have recently modified their holdings of CAPR. Creek Drive Management Group LLC bought a new stake in Capricor Therapeutics during the fourth quarter worth about $1,039,000. Moody Aldrich Partners LLC bought a new position in Capricor Therapeutics in the fourth quarter valued at approximately $6,025,000. UBS Group AG grew its stake in Capricor Therapeutics by 91.0% in the fourth quarter. UBS Group AG now owns 238,216 shares of the biotechnology company’s stock valued at $6,875,000 after purchasing an additional 113,499 shares in the last quarter. HBK Sorce Advisory LLC increased its position in shares of Capricor Therapeutics by 19.4% during the 4th quarter. HBK Sorce Advisory LLC now owns 203,705 shares of the biotechnology company’s stock worth $5,879,000 after purchasing an additional 33,128 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Capricor Therapeutics by 16.1% during the 4th quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock worth $73,936,000 after purchasing an additional 355,161 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.